VICTORIA, July 11 /PRNewswire-FirstCall/ - Aspreva Pharmaceuticals Corporation , an emerging pharmaceutical company focused on increasing the pool of evidence-based medicines available for patients living with less common diseases, today announced the appointment of Dr. Richard Jones as Senior Vice President (SVP) Clinical and Regulatory Affairs. Dr. Jones will assume responsibility from Dr. Reinhard Baildon who will retire in September 2006.
Dr. Jones joined Aspreva as a Senior Vice President in March of this year. Dr. Jones has had an extensive and successful drug development career in the pharmaceutical industry with both large pharmaceutical and biotech company drug experience. This includes five years at the Johnson and Johnson owned R.W. Johnson Pharmaceutical Research Institute, an internationally recognized research organization, with expertise in pharmacological and multidisciplinary research, where he served as Vice President, Clinical Drug Evaluation and Vice President, Proof of Principle. From 1991 to 1997, Dr. Jones worked at F. Hoffmann-La Roche, where he was responsible for clinical pharmacology studies. Before joining Roche, he served as a senior pharmacologist at Merrell Dow Research Centre. His most recent position was as medical director at Syngenta in their start up biotech venture. Dr. Jones earned a B.Sc. in Pharmacology from Trinity Hall Cambridge University after which he earned a B.M. BCh from Oxford University Medical School and subsequently a D.M (Oxford). Dr. Jones is trained and certified in internal medicine, clinical pharmacology and cardiology and is a member of the Royal College of Physicians in the United Kingdom (MRCP).
Dr. Baildon joined Aspreva shortly after its formation in 2003, and has supervised the establishment of the Company's international clinical and regulatory capabilities.
Richard Glickman, Chairman and Chief Executive Officer of Aspreva commented, "Reinhard has made an enormous contribution to Aspreva's success. The legacy he leaves behind is the first-class clinical and regulatory teams he has assembled and the foundation required to execute our complex phase III programs. Thanks to Reinhard's leadership and his team, we now have an excellent platform for future growth under a new generation of leadership. We are fortunate to have someone of Dr. Jones' caliber take on this important role of leading the clinical and regulatory teams to support Aspreva's future growth."
About Aspreva Pharmaceuticals
Aspreva is an emerging pharmaceutical company focused on identifying, developing and, upon regulatory approval, commercializing new indications for approved drugs and late stage drug candidates for patients living with less common diseases. Aspreva is listed on the NASDAQ Global Select Market under the trading symbol "ASPV" and on the Toronto Stock Exchange under the trading symbol "ASV".
Statements contained herein that are not based on historical or current fact, including without limitation, statements containing the words "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "will," "would" and similar expressions constitute forward-looking statements or information within the meaning of the Private Securities Litigation Act of 1995 and applicable Canadian Securities Legislation. These include, without limitation, statements or information related to our strategy, future operations, clinical trials, prospects and plans of management. Forward-looking statements or information involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, without limitation, risks related to difficulties or delays in the progress, timing and results of our clinical trials, our ability to attract and retain collaborations relating to the development and commercialization of new indications, difficulties or delays in obtaining regulatory approval, competition from other pharmaceutical or biotechnology companies, and other risks detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities. You are cautioned not to place undue reliance on these forward-looking statements or information, which speak only as of the date of this press release. All forward-looking statements or information are qualified in their entirety by this cautionary statement, and Aspreva undertakes no obligation to revise or update any forward-looking statements or information as a result of new information, future events or otherwise after the date hereof.
CONTACT: Sage Baker, Executive Director, Corporate & Investor Affairs, Aspreva Pharmaceuticals, (250) 744-2488, ext. 270, sbaker@aspreva.com
Aspreva PharmaceuticalsCONTACT: Sage Baker, Executive Director, Corporate & Investor Affairs,Aspreva Pharmaceuticals, (250) 744-2488, ext. 270, sbaker@aspreva.com
